Recent Press Releases

Amgen Announces Webcast of 2014 Third Quarter Financial Results

THOUSAND OAKS, Calif., Oct.

Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014

FREMONT, Calif., Oct. 23, 2014 /PRNewswire/ -- Ardelyx, Inc.

The Hope Murals Project National Art Movement Culminates in Painting Event at Grand Central Terminal on October 23

Lilly Oncology On Canvas Art Competition Names 2014 Winners; E!

Lilly Reports Third-Quarter 2014 Results

INDIANAPOLIS, Oct. 23, 2014 /PRNewswire/ --

NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack

In draft guidance published today for consultation, NICE has recommended rivaroxaban (Xarelto, Bayer Healthcare) as an option for preventing blood clots in people who have had a heart attack as a...

LEADING RESEARCHERS JOIN BIOGEN IDEC TO ADVANCE DRUG DISCOVERY FOR NEURODEGENERATIVE DISEASES

–Christopher Henderson and Richard Ransohoff to Lead and Enhance the Company's Neurology Research and Discovery Effort– CAMBRIDGE, Mass., October 23, 2014, Biogen Idec (NASDAQ: BIIB)...

Lilly Reports Third-Quarter 2014 Results

Lilly Reports Third-Quarter 2014 Results INDIANAPOLIS, Oct. 23, 2014 /PRNewswire/ -- Third-quarter 2014 revenue declined 16 percent driven by the impact of U.S. patent expirations for Cymbalta and...

Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent

Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent DUBLIN, Oct. 23, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal...

Celgene Reports Third Quarter 2014 Operating and Financial Results

Celgene Reports Third Quarter 2014 Operating and Financial Results - 2014 Total Revenue and Adjusted Diluted EPS Guidance Raised - Phase II Data on GED-0301 Presented at United European...

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies

INDIANAPOLIS and

Abbott Reports Third-Quarter 2014 Results

- Third-Quarter Adjusted EPS Above Previous Guidance Range, Including Results From Discontinued Operations Related to Mylan Transaction -

ABBOTT PARK, Ill.,

GSK CEO and CFO Interviewed on 2014 Q3 Results

LONDON, October 22, 2014 /PRNewswire/ --

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION

BIOGEN IDEC THIRD QUARTER 2014 REVENUES INCREASE 37% TO $2.5 BILLION PLEGRIDYTM Approved in the US and EU for Multiple Sclerosis ELOCTATETM Launched in the US for Hemophilia A Rollout of...

Roche invests for the future in its Basel site

Roche invests for the future in its Basel site Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development Today Roche presented...

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.

Amgen Statement Regarding Third Point Investment

THOUSAND OAKS, Calif., Oct.

FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted...